Your new post is loading...
Full results from a Phase II clinical trial of PSMA ADC (Progenics Pharmaceuticals, Inc., Tarrytown, NY, USA), a fully human monoclonal antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC) presented at ...
Via Krishan Maggon
PSMA ADC is fully human IgG1 antibody designed to delivers the chemotherapeutic drug selectively to prostate cancer cells. It does so by targeting the three-dimensional structure of the prostate specific membrane antigen or PSMA, a protein that is a clinically validated biomarker of prostate cancer and which is overexpressed on the surface of prostate cancer cells.
The PSMA antibody is linked to the chemotherapeutic microtubule disrupting agent monomethyl auristatin E (MMAE), which inhibits cell proliferation by disrupting the cellular “backbone” required for replication. The resultant antibody-drug conjugate attaches itself to the PSMA-protein on the surface of prostate cancer cells and is designed to internalize into the cancer cell, release the active anti-cancer drug, and destroy the malignant cell.